AR120714A1 - Análogos de incretina y sus usos - Google Patents
Análogos de incretina y sus usosInfo
- Publication number
- AR120714A1 AR120714A1 ARP200103435A ARP200103435A AR120714A1 AR 120714 A1 AR120714 A1 AR 120714A1 AR P200103435 A ARP200103435 A AR P200103435A AR P200103435 A ARP200103435 A AR P200103435A AR 120714 A1 AR120714 A1 AR 120714A1
- Authority
- AR
- Argentina
- Prior art keywords
- 4pal
- aib
- glucagon
- receptors
- incretin analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Details Of Garments (AREA)
Abstract
Se proporcionan los análogos de incretina que tienen actividad en cada uno de los receptores del polipéptido insulinotrópico dependiente de glucosa (GIP), el péptido similar a glucagón-1 (GLP-1) y el glucagón (GCG). Los análogos de incretina tienen características estructurales que dan como resultado una actividad equilibrada y una duración de acción extendida en cada uno de estos receptores. También se proporcionan los métodos para tratar las enfermedades, tales como la diabetes mellitus tipo 2, la dislipidemia, el síndrome metabólico, la enfermedad del hígado graso no alcohólico, la esteatohepatitis no alcohólica y la obesidad. Reivindicación 1: Un compuesto que comprende: YX²QGTX⁶TSDX¹⁰SIX¹³LDX¹⁶X¹⁷AQX²⁰X²¹FIX²⁴X²⁵LLEGGPSSGEPPPX³⁹, en donde X² es Aib, X⁶ es aMeF(2F), X¹⁰ puede ser Y o 4Pal, X¹³ puede ser L o aMeL, X¹⁶ es Orn, X¹⁷ es cualquier aminoácido con un grupo funcional disponible para la conjugación, y el grupo funcional se conjuga con un resto de ácido graso C₁₆₋₂₂, X²⁰ puede ser 4Pal, Iva o aMeL, X²¹ puede ser A o Aib, X²⁴ puede ser E o e, X²⁵ puede ser Y o aMeY, y X³⁹ puede ser E o S (SEQ ID Nº 5), y en donde un aminoácido carboxi-terminal (C-terminal) está opcionalmente amidado; o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949661P | 2019-12-18 | 2019-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120714A1 true AR120714A1 (es) | 2022-03-09 |
Family
ID=74181298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103435A AR120714A1 (es) | 2019-12-18 | 2020-12-10 | Análogos de incretina y sus usos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230102339A1 (es) |
| EP (1) | EP4077365A1 (es) |
| JP (1) | JP7450724B2 (es) |
| KR (1) | KR20220100676A (es) |
| CN (1) | CN114787183A (es) |
| AR (1) | AR120714A1 (es) |
| AU (1) | AU2020408139B2 (es) |
| BR (1) | BR112022009396A2 (es) |
| CA (1) | CA3162245A1 (es) |
| CL (1) | CL2022001623A1 (es) |
| CO (1) | CO2022008264A2 (es) |
| CR (1) | CR20220279A (es) |
| DO (1) | DOP2022000122A (es) |
| EC (1) | ECSP22048612A (es) |
| IL (1) | IL293754A (es) |
| JO (1) | JOP20220153A1 (es) |
| MX (1) | MX2022007666A (es) |
| PE (1) | PE20221518A1 (es) |
| TW (1) | TWI795698B (es) |
| WO (1) | WO2021126695A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116710462A (zh) | 2021-01-20 | 2023-09-05 | 维京治疗公司 | 用于治疗代谢病症和肝病的组合物和方法 |
| WO2023088140A1 (zh) * | 2021-11-19 | 2023-05-25 | 南京明德新药研发有限公司 | 订合肽及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| EP3082847A1 (en) * | 2013-12-20 | 2016-10-26 | Indiana University Research and Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| MX2018008027A (es) | 2015-12-31 | 2018-11-29 | Hanmi Pharm Ind Co Ltd | Activador triple que activa receptor de glucagon, glp-1 y gip. |
| BR112018067731A2 (pt) | 2016-03-10 | 2019-01-08 | Medimmune Ltd | coagonistas de glucagon e glp-1 para o tratamento de obesidade |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| TWI809515B (zh) * | 2017-12-21 | 2023-07-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
-
2020
- 2020-12-10 TW TW109143561A patent/TWI795698B/zh active
- 2020-12-10 AR ARP200103435A patent/AR120714A1/es unknown
- 2020-12-11 MX MX2022007666A patent/MX2022007666A/es unknown
- 2020-12-11 CR CR20220279A patent/CR20220279A/es unknown
- 2020-12-11 JP JP2022537359A patent/JP7450724B2/ja active Active
- 2020-12-11 EP EP20839440.3A patent/EP4077365A1/en active Pending
- 2020-12-11 WO PCT/US2020/064512 patent/WO2021126695A1/en active Application Filing
- 2020-12-11 BR BR112022009396A patent/BR112022009396A2/pt unknown
- 2020-12-11 PE PE2022001115A patent/PE20221518A1/es unknown
- 2020-12-11 CN CN202080087802.4A patent/CN114787183A/zh active Pending
- 2020-12-11 US US17/785,758 patent/US20230102339A1/en active Pending
- 2020-12-11 JO JOP/2022/0153A patent/JOP20220153A1/ar unknown
- 2020-12-11 KR KR1020227020239A patent/KR20220100676A/ko active Search and Examination
- 2020-12-11 AU AU2020408139A patent/AU2020408139B2/en active Active
- 2020-12-11 CA CA3162245A patent/CA3162245A1/en active Pending
- 2020-12-11 IL IL293754A patent/IL293754A/en unknown
-
2022
- 2022-06-13 CO CONC2022/0008264A patent/CO2022008264A2/es unknown
- 2022-06-14 DO DO2022000122A patent/DOP2022000122A/es unknown
- 2022-06-15 CL CL2022001623A patent/CL2022001623A1/es unknown
- 2022-06-17 EC ECSENADI202248612A patent/ECSP22048612A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20220153A1 (ar) | 2023-01-30 |
| CR20220279A (es) | 2022-07-03 |
| EP4077365A1 (en) | 2022-10-26 |
| WO2021126695A1 (en) | 2021-06-24 |
| AU2020408139A1 (en) | 2022-06-09 |
| MX2022007666A (es) | 2022-07-19 |
| CA3162245A1 (en) | 2021-06-24 |
| US20230102339A1 (en) | 2023-03-30 |
| CN114787183A (zh) | 2022-07-22 |
| ECSP22048612A (es) | 2022-07-29 |
| IL293754A (en) | 2022-08-01 |
| PE20221518A1 (es) | 2022-10-04 |
| KR20220100676A (ko) | 2022-07-15 |
| DOP2022000122A (es) | 2022-07-31 |
| JP7450724B2 (ja) | 2024-03-15 |
| CL2022001623A1 (es) | 2023-01-20 |
| JP2023506952A (ja) | 2023-02-20 |
| TWI795698B (zh) | 2023-03-11 |
| TW202138385A (zh) | 2021-10-16 |
| AU2020408139B2 (en) | 2024-03-28 |
| CO2022008264A2 (es) | 2022-07-08 |
| BR112022009396A2 (pt) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120714A1 (es) | Análogos de incretina y sus usos | |
| AR104932A1 (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
| PE20211637A1 (es) | Compuestos coagonistas de gip/glp1 | |
| Bellmann-Sickert et al. | Peptide drugs to target G protein-coupled receptors | |
| JP2014526254A5 (es) | ||
| BR112017008160A8 (pt) | Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição | |
| EA202091290A1 (ru) | Аналоги инкретина и их применение | |
| AR091866A1 (es) | Analogos del glucagon | |
| PE20240215A1 (es) | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo | |
| Fridolf et al. | GLP-1 and GLP-17-36 amide: influences on basal and stimulated insulin and glucagon secretion in the mouse | |
| PA8769301A1 (es) | Coagonistas del receptor de glucagón/glp-1 | |
| US20090030178A1 (en) | Cell permeable bioactive peptide conjugates | |
| EA202091284A1 (ru) | Аналоги инкретина и их применение | |
| RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| CO5570710A2 (es) | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico | |
| PE20220938A1 (es) | Compuestos agonistas de gipr | |
| PE20240686A1 (es) | Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1) | |
| AR088636A1 (es) | Conjugados peptidicos de un agonista del receptor de glp-1 y gastrina | |
| JP7239566B2 (ja) | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 | |
| PH12020551591A1 (en) | Novel glp-1 analogues | |
| BRPI0614649A2 (pt) | polipeptìdeos hìbridos com propriedades selecionáveis | |
| US11344606B2 (en) | Parathyroid hormone fusion polypeptide | |
| AR125086A1 (es) | Composiciones que contienen análogos de incretina y usos de estas | |
| AR117619A1 (es) | Compuestos coagonistas de gip / glp1 |